Your browser is no longer supported. Please, upgrade your browser.
JAZZ Jazz Pharmaceuticals Public Limited Company weekly Stock Chart
JAZZ [NASD]
Jazz Pharmaceuticals Public Limited Company
Index- P/E21.40 EPS (ttm)6.57 Insider Own2.70% Shs Outstand60.16M Perf Week-2.14%
Market Cap8.45B Forward P/E10.83 EPS next Y12.98 Insider Trans-3.42% Shs Float58.66M Perf Month-7.96%
Income403.50M PEG1.22 EPS next Q2.89 Inst Own93.10% Short Float4.60% Perf Quarter-10.02%
Sales1.54B P/S5.48 EPS this Y22.70% Inst Trans0.27% Short Ratio6.13 Perf Half Y-7.27%
Book/sh36.62 P/B3.84 EPS next Y19.31% ROA8.30% Target Price180.30 Perf Year19.38%
Cash/sh5.31 P/C26.48 EPS next 5Y17.58% ROE20.80% 52W Range95.80 - 163.75 Perf YTD28.86%
Dividend- P/FCF13.91 EPS past 5Y19.20% ROI11.70% 52W High-14.20% Beta1.02
Dividend %- Quick Ratio2.50 Sales past 5Y40.40% Gross Margin92.80% 52W Low46.66% ATR2.95
Employees1110 Current Ratio2.60 Sales Q/Q3.50% Oper. Margin39.10% RSI (14)33.60 Volatility1.95% 2.00%
OptionableYes Debt/Eq0.76 EPS Q/Q-6.90% Profit Margin26.20% Rel Volume1.16 Prev Close140.50
ShortableYes LT Debt/Eq0.74 EarningsNov 07 AMC Payout0.00% Avg Volume440.16K Price140.50
Recom2.10 SMA20-4.32% SMA50-4.85% SMA200-2.93% Volume510,695 Change0.00%
Oct-05-17Initiated Morgan Stanley Equal-Weight $155
Sep-28-17Initiated Goldman Neutral $165
Aug-25-17Initiated H.C. Wainwright Neutral $144
May-31-17Reiterated Mizuho Neutral $150 → $144
May-15-17Initiated RBC Capital Mkts Outperform $210
Apr-06-17Downgrade Mizuho Buy → Neutral $162 → $150
Mar-21-17Reiterated Mizuho Buy $152 → $162
Feb-21-17Reiterated Mizuho Buy $127 → $152
Nov-09-16Reiterated Mizuho Buy $185 → $127
Aug-10-16Reiterated Mizuho Buy $195 → $185
Jul-19-16Reiterated Mizuho Buy $193 → $195
Jun-06-16Initiated Goldman Buy $196
May-11-16Upgrade Mizuho Neutral → Buy $137 → $193
May-11-16Reiterated UBS Buy $162 → $168
Apr-25-16Upgrade Sun Trust Rbsn Humphrey Neutral → Buy
Feb-24-16Reiterated Mizuho Neutral $140 → $124
Feb-19-16Initiated Wells Fargo Outperform
Nov-25-15Initiated Bernstein Mkt Perform
Nov-10-15Downgrade Mizuho Buy → Neutral $164 → $140
Oct-14-15Initiated Northland Capital Outperform $200
Oct-13-17 10:20AM  All that Jazz: Why this Palo Alto drug maker is growing American City Business Journals
Oct-11-17 11:42AM  ETFs with exposure to Jazz Pharmaceuticals Plc : October 11, 2017 Capital Cube
Oct-06-17 08:35AM  Genocea Biosciences (GNCA) Jumps: Stock Rises 24.8% Zacks
Oct-03-17 08:17AM  Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : JAZZ-US : October 3, 2017 Capital Cube
Sep-25-17 10:40AM  ETFs with exposure to Jazz Pharmaceuticals Plc : September 25, 2017 Capital Cube
Sep-20-17 06:30AM  3 Stocks That Are Absurdly Cheap Right Now Motley Fool
Sep-15-17 08:04AM  See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC. Markit
Sep-14-17 06:28PM  ETFs with exposure to Jazz Pharmaceuticals Plc : September 14, 2017 Capital Cube
08:04AM  See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC. Markit
Sep-13-17 11:31AM  Jazz Pharmaceuticals Plc :JAZZ-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017 Capital Cube
11:25AM  3 Pharma/Biotech Sector Bargains for a Healthy Portfolio Zacks
Sep-12-17 07:38PM  Jazz Pharmaceuticals Plc Value Analysis (NASDAQ:JAZZ) : September 12, 2017 Capital Cube
08:30AM  Fortune Magazine Names Jazz Pharmaceuticals 78th Fastest Growing Company for 2017 PR Newswire
Sep-11-17 09:02AM  Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : JAZZ-US : September 11, 2017 Capital Cube
07:36AM  Where Jazz Pharmaceuticals Erwinaze and Prialt Are Positioned after 2Q17 Market Realist
Sep-08-17 10:36AM  How Is Jazzs Defitelio Positioned after 2Q17? Market Realist
09:07AM  This Could Drive Jazz Pharmaceuticals Revenue Growth Market Realist
07:37AM  Why Jazz Pharmaceuticals Vyxeos Could Boost Revenue Growth in 2018 Market Realist
Sep-07-17 04:35PM  Behind Jazzs Strategic Collaboration with ImmunoGen Market Realist
03:06PM  How Did Jazz Pharmaceuticals Perform in 1H17? Market Realist
01:29PM  Jazz Pharmaceuticals on the Street: Analysts Recommendations after 1H17 Market Realist
07:38AM  5 Key Things You Should Watch With Jazz Pharmaceuticals Motley Fool
Sep-05-17 10:19AM  Jazz Pharmaceuticals, O'Reilly Automotive and Tesla highlighted as Zacks Bull and Bear of the Day Zacks
08:04AM  See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC. Markit
04:00AM  Bull of the Day: Jazz Pharmaceuticals (JAZZ) Zacks
Sep-01-17 12:36PM  Jazz Pharmaceuticals Announces Completion of Offering and Exercise in Full of Initial Purchasers' Option to Purchase Additional 1.50% Exchangeable Senior Notes due 2024 PR Newswire
07:36AM  Ligand Pharmaceuticals Focuses on Increasing Returns for Shareholders Market Realist
Aug-31-17 08:07PM  [$$] Former Pharma Company CPA Pleads Guilty in Insider-Trading Scheme The Wall Street Journal
01:31PM  Former Celator Pharmaceuticals accountant, three others charged with insider trading MarketWatch
11:07AM  Zacks.com featured highlights include Lantheus Holdings, Jazz Pharmaceuticals, Gray Television, Aetna and Uniti Group Zacks
10:36AM  Technology Platforms and Research Programs Drive LGNDs Partnerships Market Realist
07:50AM  Featured Company News - Jazz Pharma to Partner with ImmunoGen for the Development and Commercialization of Antibody-Drug Conjugate Products ACCESSWIRE
Aug-30-17 05:39PM  Why Investors Bid Immunogen Inc. Up Almost 12% Today Motley Fool
04:05PM  Jazz Pharmaceuticals to Present at the Wells Fargo Securities Healthcare Conference PR Newswire
11:47AM  Immunogen Inks Deal With Jazz Pharma to Develop ADC Molecule Zacks
08:56AM  ImmunoGen (IMGN) in Focus: Stock Moves 17.3% Higher Zacks
07:31AM  5 Excellent Value Stocks Based on Low PEG Ratio Zacks
Aug-29-17 04:21PM  Why Movado Group, Catalent, and ImmunoGen Jumped Today Motley Fool
01:44PM  Why ImmunoGen, Inc. Jumped Higher Today Motley Fool
10:10AM  ImmunoGen and Jazz Enter Into Global Collaboration 24/7 Wall St.
10:10AM  Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers TheStreet.com
08:02AM  See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC. Markit
06:30AM  Jazz Pharmaceuticals and ImmunoGen, Inc. Announce a Strategic Collaboration and Option Agreement to Develop and Commercialize Antibody-Drug Conjugate Products Business Wire
Aug-28-17 08:56AM  Enanta Pharmaceuticals (ENTA) Looks Good: Stock Adds 9.6% in Session Zacks
Aug-23-17 01:06PM  How Jazz Pharmaceuticals Aims to Boost Vyxeos Sales in 2017 Market Realist
11:54AM  What Jazz Pharmaceuticals Expects for Vyxeos Market Realist
11:53AM  JAZZ Is Focused on Increasing Market Adoption of Defitelio Market Realist
11:52AM  Understanding Jazz Pharmaceuticals Robust Growth Opportunities in 2017 Market Realist
09:53AM  Jazz Pharmaceuticals Is Focused on Label Expansion of Defitelio Market Realist
09:08AM  Defitelio Continues to Demonstrate Robust Demand Trends in 2017 Market Realist
09:07AM  Inside the Efficacy of JAZZs JZP-110 in Obstructive Sleep Apnea Trials Market Realist
07:38AM  Erwinaze Sales May Remain Flat in 2017 Market Realist
07:37AM  Inside the Efficacy of JAZZs JZP-110 for Excessive Sleepiness Market Realist
Aug-22-17 10:36AM  The Future of JAZZs Low-Sodium Investigational Drugs Market Realist
09:07AM  This Alone Could Boost Xyrems Addressable Market in 2018 Market Realist
08:26AM  Rally Set to Resume: Buy These 5 Value Picks on the Dip Zacks
08:05AM  See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC. Markit
07:37AM  Behind Xyrems Solid Demand Trends in 2017 Market Realist
Aug-21-17 04:05PM  Inside Jazzs Net Profit Margin Expectations for 2017 Market Realist
02:36PM  Why Jazz Is Expected to Report a Robust Revenue Growth Rate Market Realist
01:02PM  Jazz on the Street: Analysts Recommendations for JAZZ in August Market Realist
07:00AM  Featured Company News - Jazz Pharma Offers Exchangeable Senior Notes Due 2024 ACCESSWIRE
Aug-18-17 11:13AM  Jazz Securities Limited -- Moody's raises Jazz's sr. secured to Ba1 from Ba2; affirms Ba3 CFR Moody's
10:28AM  Jazz Pharmaceuticals Arm Announces $500M Senior Notes Offer Zacks
09:56AM  Biotech Movers: Jazz Shares Lower Amid Notes Offering TheStreet.com
07:00AM  Jazz Pharmaceuticals Announces Offering of $500 Million of 1.50% Exchangeable Senior Notes due 2024 PR Newswire
Aug-17-17 04:07PM  Jazz Pharmaceuticals Announces Offering of $500 Million of Exchangeable Senior Notes due 2024 PR Newswire
Aug-15-17 08:25AM  Edited Transcript of JAZZ earnings conference call or presentation 8-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
07:00AM  Earnings Review and Free Research Report: Illumina Reported Better Than Expected Revenue and Earnings Results ACCESSWIRE
Aug-12-17 08:06AM  See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC. Markit
Aug-10-17 09:03AM  The 3 Top Stocks for Your IRA in August Motley Fool
Aug-09-17 02:15PM  Jazz Pharma (JAZZ) Q2 Earnings & Revenues Miss, View Intact Zacks -6.17%
01:42PM  Stocks Pare Losses; Why Is Boeing Down When Defense Firms Are Up? Investor's Business Daily
Aug-08-17 11:05PM  Jazz misses Street 2Q forecasts Associated Press
06:04PM  Jazz misses Street 2Q forecasts Associated Press
05:19PM  Jazz Pharmaceuticals shares fall after results miss Street estimates MarketWatch
04:05PM  Jazz Pharmaceuticals Announces Second Quarter 2017 Financial Results PR Newswire
11:00AM  Investor Network: Jazz Pharmaceuticals Plc to Host Earnings Call ACCESSWIRE
Aug-07-17 10:32AM  Drug Stocks Q2 Earnings Roster for Aug 8: ACAD, JAZZ & More Zacks
Aug-03-17 05:10PM  Can Jazz Pharma (JAZZ) Spring a Surprise in Q2 Earnings? Zacks
01:00PM  Drug developer jazzed to receive FDA approval for leukemia treatment American City Business Journals
10:15AM  Jazz Pharmaceuticals Announces Webcast for Vyxeos Investor Update PR Newswire
10:10AM  Jazz Pharmaceuticals Announces FDA Approval of Vyxeos (daunorubicin and cytarabine) Liposome for Injection for the Treatment of Adults with Newly-Diagnosed Therapy-Related Acute Myeloid Leukemia (t-AML) or AML with Myelodysplasia-Related Changes (AML-MRC) PR Newswire
Aug-01-17 09:24AM  Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : JAZZ-US : August 1, 2017 Capital Cube
Jul-26-17 04:05PM  Jazz Pharmaceuticals and XL-protein GmbH Enter Into a License Agreement on PASylation® Technology to Develop Long-Acting Asparaginase Product Candidates PR Newswire
Jul-24-17 04:47PM  ETFs with exposure to Jazz Pharmaceuticals Plc : July 24, 2017 Capital Cube
04:05PM  Jazz Pharmaceuticals to Report 2017 Second Quarter Financial Results on August 8, 2017 PR Newswire
Jul-14-17 03:08PM  ETFs with exposure to Jazz Pharmaceuticals Plc : July 14, 2017 Capital Cube
Jul-12-17 04:17PM  Top 5 Biotech Stocks for 2017 Investopedia
03:25PM  Jazz Pharmaceuticals Plc Value Analysis (NASDAQ:JAZZ) : July 12, 2017 Capital Cube
Jul-11-17 09:20AM  Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : JAZZ-US : July 11, 2017 Capital Cube
Jun-30-17 04:14PM  This Rebounding Pharma Stock May Launch Another Breakout Move Investor's Business Daily
09:06AM  Why Is Barclays Optimistic about Jazz Pharmaceuticals? Market Realist
Jun-26-17 10:36AM  Edited Transcript of JAZZ earnings conference call or presentation 9-May-17 8:30pm GMT Thomson Reuters StreetEvents
Jun-22-17 08:14AM  Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : JAZZ-US : June 22, 2017 Capital Cube
Jun-18-17 07:07AM  3 Reasons Jazz Pharmaceuticals Stock Could Fall Motley Fool
Jun-15-17 11:44AM  3 Mid-Cap Stocks With Big-Cap Potential Motley Fool
Jun-13-17 04:25AM  Why Is Jazz Pharmaceuticals (JAZZ) Down 3.3% Since the Last Earnings Report? Zacks
Jun-10-17 09:09AM  3 Value Stocks for Skillful Investors Motley Fool
Jun-09-17 08:37AM  Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : JAZZ-US : June 9, 2017 Capital Cube
Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops JZP-110, which is in phase III clinical trial for the treatment of excessive sleepiness (ES) in patients with narcolepsy and obstructive sleep apnea, as well as phase II clinical trial for ES associated with Parkinson's disease; Vyxeos (CPX-351) for high-risk acute myeloid leukemia; and JZP-507 and JZP-258 to treat EDS and cataplexy in narcolepsy, as well as evaluates deuterated oxybate for narcolepsy. In addition, it sells psychiatry and other products. The company is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COZADD BRUCE CChairman & CEOOct 02Sale150.001,000150,000276,664Oct 04 05:03 PM
COZADD BRUCE CChairman & CEOSep 12Sale153.521,000153,520277,664Sep 13 07:06 PM
ENRIGHT PATRICK GDirectorAug 25Sale148.4035152,0881,717Aug 28 06:10 PM
MILLER MICHAEL PATRICKEVP, US CommercialAug 15Sale144.3820028,87621,996Aug 16 07:17 PM
Treacy PaulSVP, Technical OperationsAug 14Sale143.321,304186,88416,385Aug 15 04:59 PM
Sohn Catherine A.DirectorAug 11Sale142.3766294,2486,819Aug 14 05:33 PM
Schnee ElmarDirectorAug 11Sale142.371,199170,6995,341Aug 14 05:29 PM
RIEDEL NORBERT GDirectorAug 11Sale142.3766294,2485,656Aug 14 05:27 PM
O'Keefe Kenneth WDirectorAug 11Sale142.3766294,24812,810Aug 14 05:25 PM
McSharry Heather AnnDirectorAug 11Sale142.37717102,0776,724Aug 14 05:21 PM
Gray PeterDirectorAug 11Sale142.37717102,0787,402Aug 14 05:19 PM
ENRIGHT PATRICK GDirectorAug 11Sale142.3766294,2482,068Aug 14 05:17 PM
BERNS PAUL LDirectorAug 11Sale142.3766294,2485,937Aug 14 05:15 PM
Winningham Rick EDirectorAug 11Sale142.3766294,24811,094Aug 14 05:34 PM
Hooper Suzanne SawochkaEVP & General CounselJul 20Sale160.004,580732,80032,322Jul 21 05:47 PM
MILLER MICHAEL PATRICKEVP, US CommercialJul 17Sale154.9720030,99422,196Jul 18 06:19 PM
Hooper Suzanne SawochkaEVP & General CounselJun 23Sale160.0042067,20036,902Jun 26 07:19 PM
MILLER MICHAEL PATRICKEVP, US CommercialJun 15Sale150.6520030,13022,223Jun 16 05:26 PM
Winningham Rick EDirectorJun 01Sale150.005,000750,00010,391Jun 02 06:47 PM
MILLER MICHAEL PATRICKEVP, US CommercialMay 15Sale152.9820030,59622,423May 15 05:26 PM
COZADD BRUCE CChairman & CEOMay 11Sale153.4730,0004,604,146278,491May 12 07:14 PM
Hooper Suzanne SawochkaEVP & General CounselMay 09Sale160.002,500400,00037,149May 10 06:00 PM
WILSON KAREN JSVP, Finance & PAOApr 27Sale160.001,275204,00021,133Apr 27 07:10 PM
Hooper Suzanne SawochkaEVP & General CounselApr 27Sale160.002,500400,00039,649Apr 28 06:26 PM
MILLER MICHAEL PATRICKSVP, US CommercialApr 17Sale152.5620030,51222,562Apr 19 05:26 PM
COZADD BRUCE CChairman & CEOApr 11Sale152.121,000152,120308,491Apr 13 07:26 PM
WILSON KAREN JSVP, Finance & PAOApr 10Option Exercise51.9311,458595,00329,116Apr 11 08:29 PM
WILSON KAREN JSVP, Finance & PAOApr 10Sale152.2411,4581,744,36622,408Apr 11 08:29 PM
MILLER MICHAEL PATRICKSVP, US CommercialMar 15Sale137.8920027,57822,762Mar 16 05:35 PM
WILSON KAREN JSVP, Finance & PAOMar 08Option Exercise49.363,646179,96722,408Mar 08 05:47 PM
Treacy PaulSVP, Technical OperationsMar 06Sale131.97884116,66617,579Mar 08 05:39 PM
MILLER MICHAEL PATRICKSVP, US CommercialFeb 15Sale134.5520026,91016,486Feb 16 05:13 PM
Cox Russell J.EVP & COOJan 18Sale128.754,000515,00047,095Jan 19 06:29 PM
MILLER MICHAEL PATRICKSVP, US CommercialJan 17Sale115.9320023,18616,686Jan 18 06:32 PM
MILLER MICHAEL PATRICKSVP, US CommercialDec 15Sale103.0920020,61816,886Dec 16 05:09 PM
ENRIGHT PATRICK GDirectorDec 02Sale101.8067768,9191,365Dec 06 04:31 PM
MILLER MICHAEL PATRICKSVP, US CommercialNov 15Sale112.1920022,43816,925Nov 16 05:11 PM
O'Keefe Kenneth WDirectorNov 14Buy112.4550056,2242,000Nov 15 05:12 PM
O'Keefe Kenneth WDirectorNov 11Buy114.311,500171,4651,500Nov 15 05:12 PM